Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

Overview

Journal Curr Ther Res Clin Exp

Specialty Pharmacology

Date 2022 Jul 18

PMID 35846836

Authors

Ana Martin-Santiago

Susana Puig

Daniel Arumi

Francisco Jose Rebollo Laserna

Affiliations

Soon will be listed here.

Abstract

Objective: Evaluate the safety profile and tolerability of topical phosphodiesterase 4 (PDE4) inhibitors versus vehicle as treatment for atopic dermatitis in published studies.

Methods: A search was performed in Medline/PubMed, Web of Science, and Cochrane Library databases on September 27, 2021, by 1 evaluator, without restrictions on publication dates or languages. Terms such as , and were included. The database searches were carried out by 1 evaluator. The titles and abstracts were reviewed for the identification and evaluation of potentially eligible studies. Study selection was made by two reviewers, so there was no intra-examiner statistic at the study selection step. The full-text articles were reviewed to determine whether or not they would be included in the systematic review. Global analyses, which included studies with both unclear and low risk of bias and subanalyses of studies with a low risk of bias were performed.

Results: Out of 237 identified articles, 14 clinical trials were included in the meta-analysis. In global analyses of studies with low and unclear risk of bias, topical treatment with PDE4 inhibitors did not differ from vehicle treatment in global treatment emergent adverse events (relative risk = 0.99; 95% CI, 0.87-1.14;  = 0.94) or in serious emergent adverse events appearance (relative risk = 0.92; 95% CI, 0.39-2.20;  = 0.86). In subanalyses of studies with a low risk of bias, a reduced rate of atopic dermatitis exacerbation was observed in PDE4 inhibitors compared with the vehicle (relative risk = 0.62; 95% CI, 0.39-0.98;  = 0.04) and risk of pain at the application site was confirmed (relative risk = 2.59; 95% CI, 1.27-5.28;  = 0.01).

Conclusions: PDE4 inhibitors did not show differences from vehicle treatment in treatment emergent adverse events or serious emergent adverse events incidence. In studies with low risk of bias, PDE4 inhibitors had a statistically significant risk of producing pain and reduced occurrence of atopic dermatitis exacerbation.

Citing Articles

The role of aryl hydrocarbon receptor agonists in the treatment of vitiligo.

Bitterman D, Kabakova M, Wang J, Collins A, Patel P, Gupta N Arch Dermatol Res. 2024; 316(9):659.

PMID: 39369105 DOI: 10.1007/s00403-024-03405-2.

Topical anti-inflammatory treatments for eczema: network meta-analysis.

Lax S, Van Vogt E, Candy B, Steele L, Reynolds C, Stuart B Cochrane Database Syst Rev. 2024; 8():CD015064.

PMID: 39105474 PMC: 11301992. DOI: 10.1002/14651858.CD015064.pub2.

A Comprehensive Review of Phototherapy in Atopic Dermatitis: Mechanisms, Modalities, and Clinical Efficacy.

Molla A Cureus. 2024; 16(3):e56890.

PMID: 38665759 PMC: 11043791. DOI: 10.7759/cureus.56890.

Advancing Treatment in Atopic Dermatitis: A Comprehensive Review of Clinical Efficacy, Safety, and Comparative Insights Into Corticosteroids, Calcineurin Inhibitors, and Phosphodiesterase-4 Inhibitors as Topical Therapies.

Hernandez T, Aleman S, Bao-Loc-Trung M, Forte M, Brandt W, Armstrong C Cureus. 2024; 16(3):e55393.

PMID: 38562326 PMC: 10982833. DOI: 10.7759/cureus.55393.

The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update.

Cetinarslan T, Kumper L, Folster-Holst R Front Mol Biosci. 2023; 10:1159404.

PMID: 37654796 PMC: 10467310. DOI: 10.3389/fmolb.2023.1159404.

References

Abedz N, Pawliczak R . Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. Postepy Dermatol Alergol. 2020; 36(6):752-759. PMC: 6986278. DOI: 10.5114/ada.2019.91425. View

Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C . Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2010; 164(2):415-28. DOI: 10.1111/j.1365-2133.2010.10030.x. View

Ring J, Mohrenschlager M, Henkel V . The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008; 31(3):185-98. DOI: 10.2165/00002018-200831030-00001. View

Kucharekova M, Hornix M, Ashikaga T, Tkint S, de Jongh G, Schalkwijk J . The effect of the PDE-4 inhibitor (cipamfylline) in two human models of irritant contact dermatitis. Arch Dermatol Res. 2003; 295(1):29-32. DOI: 10.1007/s00403-003-0389-4. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021; 74(9):790-799. DOI: 10.1016/j.rec.2021.07.010. View

Danby S, Draelos Z, Stein Gold L, Cha A, Vlahos B, Aikman L . Vehicles for atopic dermatitis therapies: more than just a placebo. J Dermatolog Treat. 2020; 33(2):685-698. DOI: 10.1080/09546634.2020.1789050. View

Czarnowicki T, Krueger J, Guttman-Yassky E . Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017; 139(6):1723-1734. DOI: 10.1016/j.jaci.2017.04.004. View

Silverberg J, Tallman A, Ports W, Gerber R, Tan H, Zielinski M . Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area. Acta Derm Venereol. 2020; 100(13):adv00170. PMC: 9175045. DOI: 10.2340/00015555-3489. View

Ono R, Yagi M, Shoji A, Fujita K, Yoshida M, Ports W . Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 2019; 47(1):25-32. DOI: 10.1111/1346-8138.15123. View

10.

Simpson E, Paller A, Boguniewicz M, Eichenfield L, Feldman S, Silverberg J . Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families. Dermatol Ther (Heidelb). 2018; 8(4):605-619. PMC: 6261115. DOI: 10.1007/s13555-018-0263-0. View

11.

Calverley P, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri L . Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 176(2):154-61. DOI: 10.1164/rccm.200610-1563OC. View

12.

Callender V, F Alexis A, Stein Gold L, Lebwohl M, Paller A, Desai S . Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. Am J Clin Dermatol. 2019; 20(5):711-723. PMC: 6764931. DOI: 10.1007/s40257-019-00450-w. View

13.

Shamsudin N, Fleischer Jr A . Vehicle or placebo? Investigators use incorrect terminology in randomized controlled trials half of the time: a systematic review of randomized controlled trials published in three major dermatology journals. J Drugs Dermatol. 2010; 9(10):1221-6. View

14.

Ishii N, Shirato M, Wakita H, Miyazaki K, Takase Y, Asano O . Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013; 346(1):105-12. DOI: 10.1124/jpet.113.205542. View

15.

Yang H, Wang J, Zhang X, Zhang Y, Qin Z, Wang H . Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019; 155(5):585-593. PMC: 6507295. DOI: 10.1001/jamadermatol.2019.0008. View

16.

Furue M, Kitahara Y, Akama H, Hojo S, Hayashi N, Nakagawa H . Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014; 41(7):577-85. DOI: 10.1111/1346-8138.12534. View

17.

Nemoto O, Hayashi N, Kitahara Y, Furue M, Hojo S, Nomoto M . Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial. J Dermatol. 2015; 43(8):881-7. DOI: 10.1111/1346-8138.13231. View

18.

Ohba F, Matsuki S, Imayama S, Matsuguma K, Hojo S, Nomoto M . Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study. J Dermatolog Treat. 2016; 27(5):467-72. DOI: 10.3109/09546634.2016.1157257. View

19.

Saeki H, Baba N, Oshiden K, Abe Y, Tsubouchi H . Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with.... J Dermatol. 2019; 47(1):17-24. PMC: 6972691. DOI: 10.1111/1346-8138.15137. View

20.

Hanifin J, Ellis C, Frieden I, Folster-Holst R, Stein Gold L, Secci A . OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016; 75(2):297-305. DOI: 10.1016/j.jaad.2016.04.001. View